Clazakizumab not checked
CSL Behring · CSL300 · BMS-945429
FollowEvery change as it happens, and a Monday email
Trials
2 active
9 in total · 1 in the EU
What this is
- How it works
- An antibody: a lab-made immune protein built to latch onto one target in the body.-mab: monoclonal antibodies WHO name stem
- How it’s given
- “CSL300 is a humanized anti-interleukin 6 (anti-IL-6) monoclonal antibody (mAb).”In the company’s words, NCT07619820 on ClinicalTrials.gov
- Main trialPhase 2/3
- “This is a two-part, phase 2b and phase 3 combined prospective, interventional, multicenter, randomized, double-blind, placebo-controlled study. Part 1: Phase 2b is a dose-finding study for CSL300 vs placebo. Part 2: Phase 3 aims to assess the efficacy of CSL300 vs placebo on cardiovascular (CV) outcomes and safety in subjects with systemic inflammation and either atherosclerotic cardiovascular disease (ASCVD) or diabetes with end stage kidney disease (ESKD) undergoing maintenance dialysis.”In the company’s words, NCT05485961 on ClinicalTrials.gov
- Other names
- CSL300 · BMS-945429 · ALD518
Other drugs for End Stage Kidney Disease
- Migalastat HClAmicus Therapeutics · Phase 3
- XyloCore StrenghtIperboreal Pharma Srl · Phase 3
- TegoprubartEledon Pharmaceuticals · Phase 3
- SymvessHumacyte, Inc. · Phase 3
- RoxadustatAstellas · Phase 3
- RetatrutideEli Lilly · Phase 3
Coming up2
- 30 Aug 2027Phase 1 trial completes · ClinicalTrials.gov
- 22 May 2029Phase 2/3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials9
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2/3Recruiting | 22 May 2029 | Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD) | |
| Phase 1Recruiting | 30 Aug 2027 | A Phase 1b Study to Evaluate the PK of CSL300 (Clazakizumab) in Chinese Subjects With End Stage Kidney Disease (ESKD) | |
| Phase 3Terminated | 8 Apr 2024 | Clazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant Recipients | |
| Phase 2Completed | Sep 2012 | Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate | |
| Phase 2Terminated | Apr 2013 | Safety and Efficacy of ALD518 for Reducing Oral Mucositis in Head and Neck Cancer Subjects | |
| Phase 2Completed | Jun 2013 | Psoriatic Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to NSAIDs or Non-biologic Disease Modifying Anti-rheumatic Drugs (DMARDs) Therapy | |
| Phase 2Completed | Jun 2013 | Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis | |
| Phase 2Terminated | Dec 2013 | Dose Ranging Study of BMS-945429 in Subjects With Moderate to Severe Crohn's Disease | |
| Phase 1/2Terminated | Mar 2013 | Exploratory Safety Study of ALD518 in Subjects With Steroid-refractory Acute Graft Versus Host Disease (GVHD) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026